has been cited by the following article(s):
|
[1]
|
Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol
Current Eye Research,
2023
DOI:10.1080/02713683.2023.2168013
|
|
|
|
|
[2]
|
Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol
Current Eye Research,
2023
DOI:10.1080/02713683.2023.2168013
|
|
|
|
|
[3]
|
Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema
Patient Preference and Adherence,
2023
DOI:10.2147/PPA.S427209
|
|
|
|
|
[4]
|
Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema
World Journal of Diabetes,
2021
DOI:10.4239/wjd.v12.i8.1220
|
|
|
|
|
[5]
|
Bilateral Severe Sterile Inflammation with Hypopyon after Simultaneous Intravitreal Triamcinolone Acetonide and Aflibercept Injection in a Patient with Bilateral Marked Rubeosis Associated with Ocular Ischemic Syndrome
Case Reports in Ophthalmological Medicine,
2017
DOI:10.1155/2017/5123963
|
|
|
|